IMC and Calmino are collaborating to treat irritable bowel syndrome.

Immuron Limited (ASX: IMC) has signed an exclusive distribution agreement for Australia and New Zealand to launch ProIBS, a certified medical device for managing symptoms of irritable bowel syndrome. The agreement, which includes all marketing and sales activities, expands Immuron’s digestive health portfolio alongside the rapidly growing Travelan brand. IBS affects nearly 30% of people, with symptoms such as abdominal pain, bloating, and irregular bowel movements. The Australian IBS treatment market is expected to generate AU$221.14 million in 2025, with an annual growth rate of 3.28%.

ProIBS contains AVH200, derived from Aloe barbadensis, which supports the intestinal mucosal barrier. The product has been on the Swedish pharmacy market for over a decade and has strong clinical backing, with 94% of users reporting benefits. Immuron’s Chief Commercial Officer, Flavio Palumbo, sees ProIBS as a premium, science-backed solution for pharmacists and consumers. The agreement, effective immediately, runs for five years with an option to extend while intellectual property remains with Calmino.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com